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Abstract
Background: Malignant gliomas recur even after extensive surgery and chemo-radiotherapy.
Although a relatively novel chemotherapeutic agent, temozolomide (TMZ), has demonstrated
promising activity against recurrent glioma, the effects last only a few months and drug resistance
develops thereafter in most cases. Induction of O6-methylguanine-DNA methyltransferase
(MGMT) in tumors is considered to be responsible for resistance to TMZ. Interferon-beta has been
reported to suppress MGMT in an experimental glioma model. Here we report a patient with
TMZ-refractory anaplastic astrocytoma (AA) who was treated successfully with a combination of
interferon-beta and TMZ.
Case presentation: A patient with recurrent AA after radiation-chemotherapy and stereotactic
radiotherapy was treated with TMZ. After 6 cycles, the tumor became refractory to TMZ, and the
patient was treated with interferon-beta at 3 × 106 international units/body, followed by 5
consecutive days of 200 mg/m2 TMZ in cycles of 28 days. After the second cycle the tumor
decreased in size by 50% (PR). The tumor showed further shrinkage after 8 months and the
patient's KPS improved from 70% to 100%. The immunohistochemical study of the initial tumor
specimen confirmed positive MGMT protein expression.
Conclusion: It is considered that interferon-beta pre-administration increased the TMZ sensitivity
of the glioma, which had been refractory to TMZ monotherapy.
Background
Treatment modalities for recurrent glioma are limited.
Since surgery or local radiotherapy can be applied only to
limited patients, a more systemic approach such as chem-
otherapy is used in most cases. Until recently, however,
chemotherapy has had only a limited impact for control
of recurrent glioma. A relatively novel chemotherapeutic
agent, temozolomide (TMZ), has demonstrated promis-
ing activity against recurrent glioma in some patients,
however the effects last only a few months and drug resist-
ance develops thereafter in most cases[1,2]. Resistance to
TMZ is considered to be mediated, at least to some extent,
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by a DNA repair enzyme, MGMT (O6-methylguanine-
DNA methyltransferase), which is induced in the tumor
[3]. Interferon-beta has been reported to suppress MGMT
in an experimental glioma model [4,5]. Here we report
the successful use of a combination of interferon-beta and
TMZ for treatment of recurrent anaplastic astrocytoma
after failure of TMZ monotherapy.
Case presentation
A 51-year-old man was found to have a diffusely infiltra-
tive tumor in the bilateral frontal lobe and right thalamus
(Figure 1A). The patient had undergone removal of a right
frontal tumor, diagnosed as anaplastic astrocytoma (AA),
on February 18, 2005. During local 60 Gy irradiation,
chemotherapy consisting of procarbazine, nimustine
hydrochloride (ACNU) and vincristine was given. After
the radiation-chemotherapy, MRI showed complete dis-
appearance of the lesion, including the thalamic tumor
(Figure 1B). This combination chemotherapy was
repeated every 3 months, but MRI on November 16, 2005,
revealed recurrence in the right thalamus (Figure 1C). The
patient received stereotaxic radiotherapy with 18 Gy (tar-
get volume 0.8 ml) for the recurrence in the thalamus, but
follow-up MRI in January 2006 showed enlargement of
the thalamic mass (Figure 1D). 
To differentiate radiation necrosis from recurrence, a
fluorodeoxy glucose (FDG) PET study was performed. As
the FDG-PET findings strongly suggested recurrence, TMZ
chemotherapy was started. The patient was treated with
the usual 5-day protocol repeated in cycles every 28 days,
i.e. TMZ 150 mg/m2 for the first 5 days, escalated to 200
mg/m2 in the following cycles. Although the TMZ chemo-
therapy seemed to have some effect, the tumor continued
to grow. After 6 cycles, the patient developed dysarthria
and hemiparesis, and Karnofsky performance status (KPS)
decreased from 100% to 70%. From the clinical course,
the serial MRI findings (Figure 1C, 1D, 1E) and the previ-
ous FDG-PET data, we considered this was due to progres-
sion of the recurrent disease, and therefore we abandoned
TMZ monotherapy. After application to the IRB, and with
the informed consent of the patient, a combination of
interferon-beta and TMZ treatment was started. On July
12, 2006, 3 × 106 international unit (IU)/body interferon-
beta (Feron®) was given intravenously followed by 5 days
of 200 mg/m2 TMZ (Days 2 – 6). 
The patient's neurological symptoms improved after this
first cycle, and MRI after the second cycle showed shrink-
age of the tumor (Figure 1F). The patient's neurological
symptoms also showed further concomitant improve-
ment. This treatment was repeated every 28 days. After 8
cycles, the tumor showed further shrinkage, and since
then the patient's condition has been improving, with a
KPS of 100 in April 2007. During this treatment, no ster-
oid has been administered and there have been no signif-
icant side effects exceeding grade 3 in terms of
hematological and other clinical parameters.
Immunohistochemical study to examine MGMT protein 
expression
The MGMT protein expression of the tumor specimen
taken at the initial surgery was performed using immuno-
histochemical method as described previously [6]. Briefly,
after antigen retrieval through autoclave treatment, the tis-
sue sections were incubated in 0.3% hydrogen peroxidase
for 30 min, then were incubated with the Ready-to Use
anti-MGMT monoclonal antibody (clone MT3.1, Lab
Vision, CA) overnight at 4°C. The sections were treated
with a second biotinylated antibody (DAKO) then were
incubated with streptavidin-biotin-peroxidase (SAB)
complex (DAKO). Visualization was carried out with 3',3'-
diaminobenzidine tetrahydrochloride (DAB).
More than 40% of the tumor cells were positive for this
staining thus it is confirmed that this tumor moder-
ately[6]expressed MGMT protein (Figure 2).
Discussion
We have reported a case of TMZ-refractory glioma that was
treated successfully with interferon-beta and TMZ combi-
nation therapy. Although TMZ is one of the most effective
chemotherapeutic agents for treatment of glioma recur-
rence, not all patients benefit from the drug. The response
rate of glioblastoma (GBM) or AA to the standard TMZ
protocol of 5 days in a 28-day cycle is 7–30% [1,2,7,8].
The median progression-free survival is only 2.1 months
for GBM and 5.4 months for AA [2,7]. Once resistance has
developed, there is no established management protocol.
For TMZ, 21 consecutive days of treatment followed by 7
days of drug withdrawal ("21 days on and 7 days off") [9]
or "7 days on and 7 days off" [10] or low-dose continuous
treatment with TMZ have been tried [11]. Cyclophospha-
mide treatment has also been attempted [13]. However,
all of these alternative treatments seem to have only lim-
ited effects. One of the mechanisms leading to TMZ resist-
ance is the production of a DNA repair enzyme, MGMT
[3,14]. High levels of MGMT activity in tumor cells create
resistance by blunting the therapeutic effect of TMZ, lead-
ing to treatment failure. The tumor specimen of the
present case taken at initial surgery showed that more
than 40% of the cells expressed MTMT protein which
might lead to the relative resistance to the TMZ mono-
therapy.
Interferon-beta has been used in Japan as an adjuvant
therapy for some patients with malignant glioma [15]. It
has a direct tumor-suppressive effect [16], and also acts as
an immunomodulator [12] and anti-angiogenetic agent
[17,18]. Recently, Natsume and Park showed that inter-World Journal of Surgical Oncology 2007, 5:89 http://www.wjso.com/content/5/1/89
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feron-beta lowers the activity of MGMT and enhances the
effect of TMZ in vivo and in vitro [4,5]. We administered
interferon-beta before administration of TMZ to a patient
whose recurrent AA had become refractory to standard
TMZ monotherapy. The tumor showed a partial response
after the second cycle, and thereafter the patient's condi-
tion improved and remained good for 8 months.
Although interferon-beta itself has an antitumor effect
against glioma, its effect is relatively mild, and one or two
administrations of 3 × 108 IU/body is far less than that
needed for adequate control. However, this dose may
allow attainment of a serum concentration about one
fourth of that shown to suppress MGMT activity in an in
vitro setting [5]. It is speculated that although the tumor
was initially resistant to TMZ monotherapy because of
positive MGMT protein expression, the interferon-beta
suppressed MGMT expression by the tumor, thus render-
ing it sensitive to interferon-TMZ combination treatment.
The MRI enhancement after stereotactic radiotherapy
might have been due to a radiation effect. MRI is often
useless for differentiating recurrence from radiation
necrosis [19], and false positivity with FDG-PET has also
been reported [20]. However, most previously reported
tumors showing false positivity by FDG-PET or by MRI
have been weakly enhanced or accompanied by marked
and extensive central necrosis on MRI [19-21], unlike the
present case. No previously reported tumor has been as
extensive and with such a thick rim after stereotactic radi-
otherapy with a target volume as small as 0.8 ml. Moreo-
ver this thalamic lesion regressed after interferon-TMZ
combination chemotherapy, without the use of steroid.
MRI of brain Figure 1
MRI of brain. (A) Initial MRI on February 16, 2005, shows a tumor in the right and left frontal lobe as well as the right thalamus. 
(B) MRI after surgery, radiation and chemotherapy. The tumor has completely disappeared except for slight enhancement adja-
cent to the surgical margin. (C) Recurrence of the thalamic tumor despite maintenance chemotherapy on November 16, 2005. 
(D) Increase in size of the thalamic tumor two months after stereotactic radiotherapy. (E) After 6 cycles of TMZ therapy, the 
thalamic lesion enlarged, and the patient developed dysarthria and hemiparesis. (F) After 2 courses of treatment with inter-
feron-beta and TMZ, the tumor shows a partial response.World Journal of Surgical Oncology 2007, 5:89 http://www.wjso.com/content/5/1/89
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Therefore we considered that this thalamic lesion repre-
sented genuine recurrence.
This is the first clinical report of effective treatment using
a combination of interferon-beta and TMZ against TMZ-
refractory glioma. This combination warrants further test-
ing in a larger-scale clinical study.
Conclusion
Combined treatment with interferon-beta and TMZ
achieved a response in a case of TMZ-refractory recurrent
AA. This approach may be a useful salvage therapy for
patients with recurrent malignant glioma.
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